Relationship between LPA SNPs and inflammatory burden in patients with preeclampsia to address future cardiovascular risk

References

• Kamstrup PR, Tybjaerg HA, Steffensen R, et al. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA. 2009;301:2331–2339.
   PubMed Web of Science ®Google Scholar
• Clarke R, Peden JF, Hopewell JC, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med. 2009;361:2518–2528.
   PubMed Web of Science ®Google Scholar
• Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31:2844–2853.
   PubMed Web of Science ®Google Scholar
• Paré E, Parry S, McElrath TF, et al. Clinical risk factors for preeclampsia in the 21st century. Obstet Gynecol. 2014;124:763–770.
   PubMed Web of Science ®Google Scholar
• Poon LCY, Kametas NA, Chelemen T, et al. Maternal risk factors for hypertensive disorders in pregnancy: a multivariate approach. J Hum Hypertens. 2010;24:104–110.
   PubMed Web of Science ®Google Scholar
• Bazavilvaso-Rodríguez MA, Hernández-Valencia M, Santillan-Morelos JG, et al. Oxidative stress changes in pregnant patients with and without severe preeclampsia. Arch Med Res. 2011;42:195–198.
   PubMed Web of Science ®Google Scholar
• Triggle CR, Samuel SM, Ravishankar S, et al. The endothelium: influencing vascular smooth muscle in many ways. Can J Physiol Pharmacol. 2012;90:713–738.
   PubMed Web of Science ®Google Scholar
• Dubé JB, Boffa MB, Hegele RA, et al. Lipoprotein(a): more interesting than ever after 50 years. Curr Opin Lipidol. 2012;23:133–140.
   PubMed Web of Science ®Google Scholar
• McLean JW, Tomlinson JE, Kuang WJ, et al. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature. 1987;330:132–137.
   PubMed Web of Science ®Google Scholar
• Danik JS, Buring JE, Chasman DI, et al. Lipoprotein(a), polymorphisms in the LPA gene, and incident venous thromboembolism among 21483 women. J Thromb Haemost. 2013;11:205–208.
   PubMed Web of Science ®Google Scholar
• Scipione CA, Sayegh SE, Romagnuolo R, et al. Mechanistic insights into Lp(a)-induced IL-8 expression: a role for oxidized phospholipid modification of apo(a). J Lipid Res. 2015;56:2273–2285.
   PubMed Web of Science ®Google Scholar
• Takami S, Yamashita S, Kihara S, et al. Lipoprotein(a) enhances the expression of intercellular adhesion molecule-1 in cultured human umbilical vein endothelial cells. Circulation. 1998;97:721–728.
   PubMed Web of Science ®Google Scholar
• Allen S, Khan S, Tam S, et al. Expression of adhesion molecules by Lp(a): a potential novel mechanism for its atherogenicity. Faseb J. 1998;12:1765–1776.
   PubMed Web of Science ®Google Scholar
• Cho T, Jung Y, Koschinsky ML. Apolipoprotein(a), through its strong lysine-binding site in KIV 10, mediates increased endothelial cell contraction and permeability via a Rho/Rho kinase/MYPT1-dependent pathway. J Biol Chem. 2008;283:30503–30512.
   PubMed Web of Science ®Google Scholar
• Lu W, Cheng Y-C, Chen K, et al. Evidence for several independent genetic variants affecting lipoprotein (a) cholesterol levels. Hum Mol Genet. 2015;24:2390–2400.
   PubMed Web of Science ®Google Scholar
• Berglund L, Ramakrishnan R. Lipoprotein(a): an elusive cardiovascular risk factor. ATVB. 2004;24:2219–2226.
   Web of Science ®Google Scholar
• Güngör ZB, Tüten A, Ekmekçi H, et al. Possible effects of lipoprotein-associated phospholipase A2 single-nucleotide polymorphisms on cardiovascular risk in patients with preeclampsia. J Maternfetal Neonat Med. 2018;31:3119–3127.
   PubMed Web of Science ®Google Scholar
• ACOG Committee on Obstetric Practice. ACOG Practice bulletin #33: diagnosis and management of preeclampsia and eclampsia. Obstet Gynecol. 2002;99:159–167.
   PubMed Web of Science ®Google Scholar
• Hobbs HH, White AL. Lipoprotein(a): intrigues and insights. Curr Opin Lipidol. 1999;10:225–236.
   PubMed Web of Science ®Google Scholar
• Tsimikas S, Hall JL. Lipoprotein(a) as a potential causal genetic risk factor of cardiovascular disease. J Am Coll Cardiol. 2012;60:716–721.
   PubMed Web of Science ®Google Scholar
• Barlera S, Specchia C, Farrall M, et al. Multiple QTL influence the serum Lp(a) concentration: a genome-wide linkage screen in the PROCARDIS study. Eur J Hum Genet. 2007;15:221–227.
   PubMed Web of Science ®Google Scholar
• Khalifa M, Noureen A, Ertelthalner K, et al. Lack of association of rs3798220 with small apolipoprotein(a) isoforms and high lipoprotein(a) levels in East and Southeast Asians. Atherosclerosis. 2015;242:521–528.
   PubMed Web of Science ®Google Scholar
• Bushnell C, McCullough LD, Awad IA, et al. Guidelines for the prevention of stroke in women: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45:1545–1588.
   PubMed Web of Science ®Google Scholar
• Mosca L, Benjamin EJ, Berra K, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women – 2011 update: a guideline from the American Heart Association. J Am Coll Cardiol. 2011;57:1404–1423.
   PubMed Web of Science ®Google Scholar
• Balcı Ekmekçi Ö, Ekmekçi H, Güngör Z, et al. Evaluation of Lp-PLA2 mass, Vitronectin and PAI-1 activity levels in patients with preeclampsia. Arch Gynecol Obstet. 2015;292:53–58.
   PubMed Web of Science ®Google Scholar
• Drost JT, Arpaci G, Ottervanger JP, et al. Cardiovascular risk factors in women 10 years post earlypreeclampsia: the preeclampsia Risk EValuation in FEMales study (PREVFEM). Eur J Prev Cardiolog. 2012;19:1138–1144.
   PubMed Web of Science ®Google Scholar
• Veerbeek JHW, Hermes W, Breimer AY, et al. Cardiovascular disease risk factors after early-onset preeclampsia, late-onset preeclampsia, and pregnancy-induced hypertension. Hypertension. 2015;65:600–606.
   PubMed Web of Science ®Google Scholar
• Nielsen LB. Atherogenecity of lipoprotein(a) and oxidized low density lipoprotein: insight from in vivo studies of arterial wall influx, degradation and efflux. Atherosclerosis. 1999;143:229–243.
   PubMed Web of Science ®Google Scholar
• Tsimikas S, Brilakis ES, Miller ER, et al. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med. 2005;353:46–57.
   PubMed Web of Science ®Google Scholar
• Winkler K, Winkelmann BR, Scharnagl H, et al. Platelet-activating factor acetylhydrolase activity indicates angiographic coronary artery disease independently of systemic inflammation and other risk factors. Circulation. 2005;111:980–987.
   PubMed Web of Science ®Google Scholar
• Tselepis AD, John Chapman MJ. Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase. Atherosclerosis. 2002;3:57–68.
   PubMed Web of Science ®Google Scholar
• Tellis CC, Tselepis AD. Τhe role of lipoprotein-associated phospholipase A2 in atherosclerosis may depend on its lipoprotein carrier in plasma. Biochim Biophys Acta. 2009;1791:327–338.
   PubMed Web of Science ®Google Scholar
• Karabina SP, Elisaf MC, Goudevenos J, et al. PAF-acetylhydrolase activity on Lp(a) before and during Cu2+-induced oxidative modification in vitro. Atherosclerosis. 1996;125:121–134.
   PubMed Web of Science ®Google Scholar
• Blencowe C, Hermetter A, Kostner GM, et al. Enhanced association of platelet-activating factor acetylhydrolase with lipoprotein (a) in comparison with low density lipoprotein. J Biol Chem. 1995;270:31151–31157.
   PubMed Web of Science ®Google Scholar
• Subbanagounder G, Wong JW, Lee H, et al. Epoxyisoprostane and epoxycyclopentenone phospholipids regulate monocyte chemotactic protein-1 and interleukin-8 synthesis. J Biol Chem. 2002;277:7271–7281.
   PubMed Web of Science ®Google Scholar
• Huo Y, Weber C, Forlow SB, et al. The chemokine KC, but not monocyte chemoattractant protein-1, triggers monocyte arrest on early atherosclerotic endothelium. J Clin Invest. 2001;108:1307–1314.
   PubMed Web of Science ®Google Scholar
• Berliner JA, Gharavi NM. Endothelial cell regulation by phospholipid oxidation products. Free Radic Biol Med. 2008;45:119–123.
   PubMed Web of Science ®Google Scholar
• Gargalovic PS, Imura M, Zhang B, et al. Identification of inflammatory gene modules based on variations of human endothelial cell responses to oxidized lipids. Proc Natl Acad Sci USA. 2006;103:12741–12746.
   PubMed Web of Science ®Google Scholar
• Savchenko A, Imamura M, Ohashi R, et al. Expression of PENTRAXIN 3 (PTX3) in human atherosclerotic lesions. J Pathol. 2008;215:48–55.
   PubMed Web of Science ®Google Scholar
• Uhlar CM, Whitehead AS. Serum amyloid A, the major vertebrate acute-phase reactant. Eur J Biochem. 1999;265:501–523.
   PubMedGoogle Scholar
• Basile A, Sica A, d’Aniello E, et al. Characterization of the promoter for the human long pentraxin PTX3. J Biol Chem. 1997;272:8172–8178.
   PubMed Web of Science ®Google Scholar
• Enkhmaa B, Anuurad E, Öztürk Z, et al. Differential associations of serum amyloid A and pentraxin-3 with allele-specific lipoprotein(a) levels in African Americans and Caucasians. Transl Res. 2011;158:92–98.
   PubMed Web of Science ®Google Scholar